（於開曼群島註冊成立的有限公司） （股份代號：3696） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 英矽智能與太景的合作達成里程碑， 對外授權的CKD貧血新藥ISM4808完成I期臨床首例受試者入組並給藥 本公告由英矽智能（「本公司」，連同其附屬公司統稱「本集團」）自願作出，以告知 本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，公司此前對外授權給太景（股票代碼：4157. TWO）的慢性腎病(CKD)貧血創新藥ISM4808已達成首個協議里程碑。近日，太 景已順利完成該項AI驅動的PHD抑制劑I期臨床試驗的首例受試者入組及給藥。 該項臨床試驗為隨機、雙盲、安慰劑對照研究，包含單次給藥(SAD)及多次給藥 (MAD)部分，旨在評估ISM4808在健康成年人中的安全性、耐受性及藥代動力學 特徵。 ...

Core Insights - The company has completed the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA, which focuses on treating inflammatory bowel disease (IBD) [1] - The company has entered into a licensing collaboration with TaiJing for another innovative candidate drug ISM4808, aimed at treating anemia related to chronic kidney disease (CKD), with a total collaboration value of tens of millions of dollars [2] Group 1 - The innovative candidate drug ISM5411, developed with the assistance of the company's proprietary AI platform Pharma.AI, has received the official generic name Garutadustat from the USAN Council [1] - The ongoing multi-center, randomized, double-blind, placebo-controlled Phase IIa clinical study will evaluate the clinical application potential of Garutadustat in approximately 80 patients with ulcerative colitis (UC), focusing on safety, tolerability, and pharmacokinetic (PK) characteristics [1] - The study will explore efficacy signals through various multidimensional indicators, including clinical remission/response, endoscopic examination, histopathology, and biomarkers [1] Group 2 - The collaboration with TaiJing aims to leverage clinical and market expertise alongside the company's AI-driven drug development efficiency to address unmet medical needs [2] - The integration of advanced AI and automation technologies has significantly enhanced early-stage new drug development efficiency, setting a benchmark for AI-driven drug development [2] - Compared to the traditional drug development cycle of approximately 4.5 years, the company's self-research projects from 2021 to 2024 have an average timeline of only 12-18 months from project initiation to PCC nomination, requiring the synthesis and testing of about 60-200 molecules per project [2]

Core Insights - The company, Yingkui Intelligent (03696), has completed the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA, aimed at treating inflammatory bowel disease (IBD) [1] - The generic name Garutadustat for ISM5411 has been officially approved by the USAN Council, indicating regulatory progress for the drug [1] - The ongoing multi-center, randomized, double-blind, placebo-controlled Phase IIa study will evaluate the clinical application potential of Garutadustat in approximately 80 patients with ulcerative colitis (UC), focusing on safety, tolerability, pharmacokinetics (PK), and efficacy signals through various multidimensional indicators [1] Company Developments - Yingkui Intelligent has entered into an external licensing collaboration with Taijing for another innovative candidate drug ISM4808, aimed at treating anemia related to chronic kidney disease (CKD), with a total collaboration value of tens of millions of dollars [2] - The collaboration aims to leverage Taijing's clinical and market expertise alongside Yingkui Intelligent's AI-driven drug development efficiency to address unmet medical needs [2] - The company has significantly enhanced early-stage new drug development efficiency through the integration of advanced AI and automation technologies, setting a benchmark for AI-driven drug development [2] - Compared to the traditional drug development cycle of approximately 4.5 years, Yingkui Intelligent's self-research projects from 2021 to 2024 have an average timeline of only 12-18 months from project initiation to PCC nomination, requiring the synthesis and testing of about 60-200 molecules per project [2]